“…Moreover, there are a number of difficulties in measuring disease activity in patients with axPsA. Several previous studies reported that clinical features of axPsA including inflammatory back pain and limitation of spinal ASDAS-CRP ankylosing spondylitis disease activity score C-reactive protein, ASDAS-ESR ankylosing spondylitis disease activity score erythrocyte sedimentation rate, VAS pain visual analog scale for pain, BASDAI bath ankylosing spondylitis disease activity index, BASFI bath ankylosing spondylitis functional index, ESR erythrocyte sedimentation rate, CRP C-reactive protein, ASQoL ankylosing spondylitis quality of life questionnaire ASDAS-CRP ankylosing spondylitis disease activity score C-reactive protein, ASDAS-ESR ankylosing spondylitis disease activity score erythrocyte sedimentation rate, VAS pain visual analog scale for pain, BASDAI bath ankylosing spondylitis disease activity index, BASFI bath ankylosing spondylitis functional index, ESR erythrocyte sedimentation rate; CRP C-reactive protein, ASQoL ankylosing spondylitis quality of life questionnaire mobility as well as radiologic features are usually less severe than AS [7,8]. Furthermore, many of the patients with axPsA may be asymptomatic or have subclinical axial symptoms despite their spinal involvement [23].…”